Stem Cell Clinic

Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed…

By Global News Feed

SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). The trials will evaluate the safety, pharmacokinetics and efficacy of a single injection of STI-2020 in healthy volunteers and outpatient COVID-19 patients with mild symptoms.

See more here:
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trials for STI-2020 (COVI-AMG) in Healthy Volunteers and in Newly Diagnosed...

Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020

By Global News Feed

– Data demonstrate potential of Amunix’s XPAT (XTENylated Protease-Activated T cell engager) platform to mitigate on-target, off-tumor toxicity that has hindered success of T cell engagers in treating solid tumors –

Go here to read the rest:
Amunix Presents Preclinical Data on AMX-818, a Protease-Activated HER2-Targeted T Cell Engager Prodrug, at SABCS 2020

Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO

By Global News Feed

NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that a clinical update on DANYELZA® (naxitamab-gqgk) for the treatment of Refractory/Relapsed High-Risk Neuroblastoma was given at the ESMO Immuno-Oncology Virtual Congress 2020, which is being held December 9 through December 12, 2020. The DANYELZA data was presented by Dr. Jaume Mora from SJD Barcelona Children's Hospital, Spain and Dr. Daniel A. Morgenstern from The Hospital for Sick Children, Toronto, Canada.

More here:
Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO

SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer…

By Global News Feed

SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 San Antonio Breast Cancer Symposium, taking place virtually from December 8-11, 2020.

Read the rest here:
SEngine Precision Medicine Presents Data Summarizing Predictive Value of PARIS® Test in Breast Cancer Patients at 2020 San Antonio Breast Cancer...

Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in…

By Global News Feed

–EDP1908 announced as clinical candidate in oncology after showing superior preclinical activity over EDP1503––Interim clinical data for EDP1503 suggest potential of orally delivered SINTAX™ product candidates to activate systemic immunity–

Continued here:
Evelo Biosciences Announces New Clinical Candidate in Oncology and Presents Additional Interim Data from Phase 1/2 Clinical Trial of EDP1503 in...

Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020

By Global News Feed

WESTLAKE VILLAGE, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced continued progress and future growth drivers related to its immuno-dermatology platform and pipeline, which will be highlighted during today’s Virtual Investor Day at 11:00 am ET.

View post:
Arcutis Highlights Advanced Pipeline & Unique Immuno-Dermatology Drug Development Capabilities at Virtual Investor Day on December 9, 2020

CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

By Global News Feed

MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced new preclinical data confirming the efficacy of its apelin agonist peptides in a preclinical model of acute respiratory distress syndrome (ARDS). The company expects the apelin agonists to have potential to treat COVID-19 associated ARDS as well as ARDS patients in general, of which there are approximately three million globally.

Originally posted here:
CohBar Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome (ARDS) Model

→←